"Longer follow-ups after the pandemic are needed to investigate persistent brain aging effects and their long-term ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

The Swiss drugmaker discussed the option of selling drugs directly to patients with U.S. officials following Trump ...

LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified ...

On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings ...

However, yesterday GSK announced that the FDA has extended the review period for Blenrep to give the agency time to review ...

In this exclusive Drug Digest video, Deepak Bahl from Roquette and Jagruti Patel from Lonza look at strategies for ...

Dispatch Biotherapeutics Inc. is taking aim at solid tumors with a new viral vector/antigen technology backed by major ...

Zydus Lifesciences has appealed a Delhi High Court order that restricts the company from producing and selling its biosimilar cancer drug, ZRC-3276.

Dispatch, based in Philadelphia and San Francisco, is developing a platform to carr novel antigens to solid tumors.

Rocket Pharmaceuticals will cut 80 jobs and streamline operations, focusing on gene therapies to drive long-term growth.